$60,000 of ARDELYX INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Medicare ESRD benefit and chronic kidney disease management. Most-Favored-Nation (MFN) issues."
You can find more data on corporate lobbying on Quiver Quantitative.
ARDX Insider Trading Activity
ARDX insiders have traded $ARDX stock on the open market 35 times in the past 6 months. Of those trades, 1 have been purchases and 34 have been sales.
Here’s a breakdown of recent trading of $ARDX stock by insiders over the last 6 months:
- DAVID M MOTT purchased 333,333 shares for an estimated $1,946,331
- MICHAEL RAAB (President & CEO) has made 0 purchases and 9 sales selling 217,869 shares for an estimated $1,294,353.
- LAURA A WILLIAMS (See Remarks) has made 0 purchases and 4 sales selling 64,602 shares for an estimated $432,283.
- ERIC DUANE FOSTER (Chief Commercial Officer) has made 0 purchases and 5 sales selling 16,253 shares for an estimated $93,225.
- JOSEPH JAMES REILLY (See Remarks) has made 0 purchases and 4 sales selling 16,077 shares for an estimated $90,562.
- MIKE KELLIHER (See Remarks) has made 0 purchases and 4 sales selling 15,155 shares for an estimated $86,884.
- ELIZABETH A GRAMMER (See Remarks) sold 5,995 shares for an estimated $33,193
- JOHN E BISHOP (See Remarks) has made 0 purchases and 3 sales selling 3,179 shares for an estimated $18,586.
- JAMES PARKER BRADY (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 2,543 shares for an estimated $14,867.
- SUSAN HOHENLEITNER (Chief Financial Officer) has made 0 purchases and 2 sales selling 2,033 shares for an estimated $11,886.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARDX Hedge Fund Activity
We have seen 114 institutional investors add shares of ARDX stock to their portfolio, and 111 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MACQUARIE GROUP LTD removed 10,455,588 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $60,956,078
- MILLENNIUM MANAGEMENT LLC added 4,267,524 shares (+55.8%) to their portfolio in Q4 2025, for an estimated $24,879,664
- MARSHALL WACE, LLP removed 3,754,403 shares (-42.0%) from their portfolio in Q4 2025, for an estimated $21,888,169
- STATE STREET CORP added 2,193,649 shares (+22.6%) to their portfolio in Q4 2025, for an estimated $12,788,973
- D. E. SHAW & CO., INC. removed 1,901,783 shares (-57.4%) from their portfolio in Q4 2025, for an estimated $11,087,394
- J. GOLDMAN & CO LP added 1,532,236 shares (+1693.1%) to their portfolio in Q4 2025, for an estimated $8,932,935
- QUBE RESEARCH & TECHNOLOGIES LTD added 1,096,117 shares (+inf%) to their portfolio in Q4 2025, for an estimated $6,390,362
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARDX Analyst Ratings
Wall Street analysts have issued reports on $ARDX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/20/2026
- Wedbush issued a "Outperform" rating on 01/21/2026
- Citigroup issued a "Buy" rating on 11/03/2025
- TD Cowen issued a "Buy" rating on 10/31/2025
To track analyst ratings and price targets for ARDX, check out Quiver Quantitative's $ARDX forecast page.
ARDX Price Targets
Multiple analysts have issued price targets for $ARDX recently. We have seen 6 analysts offer price targets for $ARDX in the last 6 months, with a median target of $16.5.
Here are some recent targets:
- Laura Chico from Wedbush set a target price of $19.0 on 02/23/2026
- Julian Harrison from BTIG set a target price of $17.0 on 02/20/2026
- Matthew Caufield from HC Wainwright & Co. set a target price of $18.0 on 02/20/2026
- Christopher Raymond from Piper Sandler set a target price of $16.0 on 01/09/2026
- Yigal Nochomovitz from Citigroup set a target price of $14.0 on 01/09/2026
- Joseph Thome from TD Cowen set a target price of $10.0 on 10/31/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
